Board Meeting Outcome for Intimation of Audited Financial Results under Regulation 33 of Listing Regulations.
MEDANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts more than Nifty Midcap 150 and 2.5 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Global Health Limited (Medanta) reported consolidated revenue of ₹44,103 million for FY2026, up 15.8% from ₹36,923 million in FY2025. Standalone revenue grew to ₹37,094 million from ₹32,041 million. Consolidated PAT increased to ₹5,541 million from ₹4,813 million (15.1% growth). The company recommended a final dividend of ₹0.50 per share (25% on face value of ₹2). Statutory auditors Walker Chandiok & Co LLP issued an unmodified report with no qualifications. Exceptional items of ₹10.21 million (net) for the year include labor code impact of ₹365.98 million partially offset by EPCG reversal of ₹195.92 million.
Revenue and profit growth of around 15-16% are healthy but below high-growth thresholds. Unmodified auditor opinion and strong operating cash flow of ₹7,144 million are positives. The dividend signals confidence, and expansion plans in Varanasi and Indore indicate growth focus.